A detailed history of Xtx Topco LTD transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 11,195 shares of RCUS stock, worth $175,761. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,195
Previous 38,761 71.12%
Holding current value
$175,761
Previous $590,000 71.02%
% of portfolio
0.01%
Previous 0.05%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$13.69 - $18.01 $377,378 - $496,463
-27,566 Reduced 71.12%
11,195 $171,000
Q2 2024

Aug 12, 2024

BUY
$14.59 - $18.48 $565,522 - $716,303
38,761 New
38,761 $590,000
Q3 2023

Nov 13, 2023

BUY
$17.62 - $23.54 $97,033 - $129,634
5,507 Added 33.45%
21,970 $394,000
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $279,377 - $362,679
16,463 New
16,463 $334,000
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $212,760 - $385,668
10,800 New
10,800 $223,000
Q2 2021

Aug 12, 2021

SELL
$22.75 - $35.77 $219,492 - $345,108
-9,648 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$26.16 - $41.39 $252,391 - $399,330
9,648 New
9,648 $271,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.13B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Xtx Topco LTD Portfolio

Follow Xtx Topco LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.